Are Patients at Risk for Recurrent Disease Activity After Switching From Remicade® to Remsima®? An Observational Study
Background: Since the late ‘90s, infliximab (Remicade®) is being used successfully to treat patients with several non-infectious immune mediated inflammatory diseases (IMIDs). In recent years, infliximab biosimilars, including Remsima® were introduced in clinical practice. Aim: To investigate the interchangeability of Remicade® (originator infliximab) and its biosimilar Remsima® in patients with rare immune-mediated inflammatory diseases (IMIDs). Methods: This two-phased prospective open label observational study was designed to monitor the transition from Remicade® to Remsima® in patients with rare IMIDs. All included patients were followed during the first 2 years. The primary endpoint was the demonstration of non-difference in quality of life and therapeutic efficacy, as measured by parameters including a safety monitoring program, physicians perception of disease activity (PPDA) and patient self-reported outcomes (PSROs). Secondary outcomes included routine blood analysis, pre-infusion serum drug concentration values and anti-drug antibody formation. Results: Forty eight patients treated with Remicade® were switched to Remsima® in June-July 2016 and subsequently monitored during the first 2 years. The group consisted of patients with sarcoidosis (n = 17), Behçet's disease (n = 12), non-infectious uveitis (n = 11), and other diagnoses (n = 8). There were no significant differences in PPDA, PSROs, clinical and laboratory assessments and pre-infusion serum drug concentrations between the groups. De novo anti-drug antibodies were observed in two patients. Seven patients with sarcoidosis and five with another diagnosis developed a significant disease relapse (n = 7) or adverse events (n = 5) within 2 years; 10 of these patients discontinued Remsima® treatment, one withdrew from the study and one received additional corticosteroid therapy. Conclusions: We observed no significant differences in PSROs, PPDA and laboratory parameters after treatment was switched from Remicade® to Remsima®. However, disease relapse or serious events were observed in 12 out of 48 patients when treatment was switched from Remicade® to Remsima®. The choice to switch anti-TNF alpha biologics in patients with rare IMIDs, particularly in sarcoidosis, requires well-considered decision-making and accurate monitoring due to a possibly higher incidence of disease worsening.
|Keywords||anti-TNF-alpha, biosimilar, CTP 13, fucosylation, infliximab, rare or orphan immune-mediated inflammatory diseases (IMIDs), Remicade®, Remsima®|
|Persistent URL||dx.doi.org/10.3389/fmed.2020.00418, hdl.handle.net/1765/130013|
|Journal||Frontiers in Medicine|
Xue, L. (Laixi), Van Bilsen, K, Schreurs, M.W.J, van Velthoven, M.E, Missotten, T, Thiadens, A.A.H.J, … van Hagen, P.M. (P. M.). (2020). Are Patients at Risk for Recurrent Disease Activity After Switching From Remicade® to Remsima®? An Observational Study. Frontiers in Medicine, 7. doi:10.3389/fmed.2020.00418